Compare Charles River Laboratories Intl. Inc (CRL) vs Manulife Financial Corporation (MFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Manulife Financial Corporation — how do they compare? Charles River Laboratories Intl. Inc trades at $288.87 (market cap $13.46B), while Manulife Financial Corporation trades at $43.84 (market cap $72.68B). The key difference: Manulife Financial Corporation is far larger — about 5.4× Charles River Laboratories Intl. Inc's market cap, and Manulife Financial Corporation pays a 3.1% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | MFC | |
|---|---|---|
Market Cap | $13.46B | $72.68B |
Sector | Health | Financials |
52-Week High | $282.00 | $44.77 |
52-Week Low | $145.57 | $30.06 |
Enterprise Value | $16.30B | $67.84B |
Dividend Yield | — | 3.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.
The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.
MFC trades at $43.88, down 0.61% on the day, with a neutral technical signal despite bullish moving averages. The company reported Q2 2026 EPS of $0.79, beating estimates, driven by 21% APE sales growth in Asia. Revenue reached $53.01B in 2025, with net income margin at 11.7%. Recent news highlights AI partnerships with Microsoft and Alibaba Cloud, enhancing operational efficiency.
Outlook is positive with 57% analyst buy ratings and a $51.50 consensus target, though premium valuation (P/E 16.57) and mixed earnings history pose risks. Strengths include robust cash flow and dividend consistency, but investors face headwinds from competitive pressures and regulatory scrutiny in Asian markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →
